An overview on Thrombocytopenia

Pharmacy, pharmacology

Thrombocytopenia is common in intensive care patients and causes increased morbidity and mortality due to complications such as bleeding and transfusion. This is due to many factors such as platinum depletion, tracking, destruction and consumption. It is important to fully understand this process for correct diagnosis and treatment. Treatment strategies focus on controlling the implant problem by administering injections such as platinum to treat complications such as bleeding. Recent research supports the use of blood transfusion as a treatment option. This review focuses on the different pathophysiological mechanisms of thrombocytopenia encountered in the intensive care unit, examining different platelet transfusion rates, alternatives, and the potential role of thromboelastography (TEG) in guiding the appropriate administration of blood to prevent correction of coagulopathy. The normal number in adults is between 150,000 and 450,000 per microlitre; More than 450,000/microliter is called thrombocytosis and less than 150,000/microliter is called thrombocytopenia. Different types of thrombocytopenia are defined according to the cause, such as immune thrombocytopenic purpura, heparin-induced thrombocytopenia, thrombocytopenic purpura, and drug-induced thrombocytopenia.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.